Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials

I Chau, D Cunningham, C Russell, A R Norman, T Kurzawinski, P Harper, P Harrison, G Middleton, F Daniels, T Hickish, J Prendeville, P J Ross, B Theis, R Hull, M Walker, N Shankley, B Kalindjian, G Murray, A Gillbanks, J Black

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients with biopsy-proven, inoperable pancreatic carcinoma were recruited. Trial A compared protracted venous infusion (PVI) gastrazole with PVI placebo, whereas trial B compared PVI gastrazole with PVI fluorouracil (5-FU). Eighteen patients were randomised in trial A. Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months; 1-year survival: 33 vs 11%, respectively; log rank P=0.02). No difference in toxicity was seen between gastrazole and placebo, except central venous catheter and pump complications. Ninety-eight patients were randomised in trial B. No significant survival difference was detected between gastrazole and 5-FU (median: 3.6 vs 4.2 months; 1-year survival: 13.2 vs 26.2%, respectively; log rank P=0.42). Toxicity of gastrazole was mild with significantly less diarrhoea (P=0.03), stomatitis (P<0.001) and hand- foot syndrome (P<0.001) compared to 5-FU. Quality of life (QoL) assessment showed similar QoL between gastrazole and 5-FU at baseline and no significant differences occurred with treatment either between arms or within arms. Compared to placebo, patients with advanced pancreatic cancer treated with gastrazole appeared to live longer, albeit in a very small trial and will require confirmation with large-scale randomised data. However, it did not produce survival advantage over PVI 5-FU. Lack of toxicity for gastrazole may allow its combination with cytotoxic drugs.

Original languageEnglish
Pages (from-to)1107-15
Number of pages9
JournalBritish Journal of Cancer
Issue number8
Publication statusPublished - 24 Apr 2006


  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Fluorouracil
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pancreatic Neoplasms
  • Pilot Projects
  • Placebos
  • Predictive Value of Tests
  • Receptor, Cholecystokinin B
  • Single-Blind Method
  • Survival Rate
  • Time Factors
  • Treatment Outcome


Dive into the research topics of 'Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials'. Together they form a unique fingerprint.

Cite this